Results 41 to 50 of about 611,304 (276)
Riociguat for Pulmonary Hypertension [PDF]
New England Journal of Medicine, 2013 open
Jaewon Oh, Jong Chan Youn, Seok Min Kang
openaire +8 more sources
Pediatric Pulmonary Hypertension
Journal of the American College of Cardiology, 2013 Pulmonary hypertension (PH) is a rare disease in newborns, infants, and children that is associated with significant morbidity and mortality. In the majority of pediatric patients, PH is idiopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease.
Ivy, D Dunbar +11 more
openaire +6 more sources
American Journal of Respiratory and Critical Care Medicine, 2015 Pulmonary hypertension is said to occur when the mean pulmonary arterial pressure exceeds 25 mmHg at rest or 30 mmHg during exercise. There are many causes but the term Pulmonary arterial hypertension (PAH) is used to describe a rare group of illnesses that share histopathological similarities in the small muscularised pulmonary arterioles leading to ...
Ali Ataya, Johan Barretto, John Wynne
openaire +4 more sources
Diagnostics, 2020 Various parameters reflecting right heart size, right ventricular function and capacitance have been shown to be prognostically important in patients with pulmonary hypertension (PH).
Ekkehard Grünig +3 more
doaj +1 more source
Pulmonary Hypertension Caused by Pulmonary Venous Hypertension [PDF]
Pulmonary Circulation, 2014 The effect of pulmonary venous hypertension (PVH) on the pulmonary circulation is extraordinarily variable, ranging from no impact on pulmonary vascular resistance (PVR) to a marked increase. The reasons for this are unknown. Both acutely reversible pulmonary vasoconstriction and pathological remodeling (especially medial hypertrophy and intimal ...
openaire +4 more sources
Arthritis Research & Therapy, 2019 Objective The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary
Zixuan Pan +15 more
doaj +1 more source
Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models. [PDF]
, 2016 Pulmonary hypertension (PH) is a complex disease comprising a pathologic remodeling and thickening of the pulmonary vessels causing an after load on the right heart ventricle that can result in ventricular failure. Triggered by oxidative stress, episodes
Ahmed, Mohamed +5 more
core +2 more sources
Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
Pulmonary Circulation, 2018 Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial ...
Nader Chebib +7 more
doaj +1 more source
Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve? [PDF]
, 2012 In the early 1990s, within three years of cloning of endothelin receptors, orally active endothelin receptor antagonists (ERAs) were tested in humans and the first clinical trial of ERA therapy in humans was published in 1995.
Barton, Matthias +4 more
core +1 more source
Molecular Oncology, EarlyView.Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho +11 more
wiley +1 more source